RxDoctor Payments Data

Edilberto Benitez, MD

Cardiovascular Disease · Gainesville, FLNPI 1104168673

Payments from drug & device makers

$43,759in general payments, 2019–2025

Across 325 payments — averaging $134.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$20K
  • Boston Scientific$10K
  • Abbott$5K
  • Medical Device Business Services, Inc.$1K
  • Biosense Webster, Inc.$1K
  • Cvrx, Inc.$784
  • plus $5K from 37 others

What the payments were for

  • Grants$23,08353%
  • Travel & lodging$8,14419%
  • Food & beverage$12,44528%
  • Education$870%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,759 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$410,520
Medicare patients
1,300
Services billed
4,501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban238$277,720
EntrestoSacubitril/Valsartan48$80,764
XareltoRivaroxaban58$59,343
Dofetilide90$19,086
FarxigaDapagliflozin Propanediol12$14,783
OzempicSemaglutide14$13,440
MultaqDronedarone Hcl15$9,591
Valsartan57$1,175
Atorvastatin Calcium98$1,026
SotalolSotalol Hcl28$827
Flecainide Acetate21$773
Metoprolol Succinate62$600
ClopidogrelClopidogrel Bisulfate23$547
Amlodipine Besylate70$473
Carvedilol76$433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$339$277,720238 claims
NovartisEntresto$360$80,76448 claims
Johnson & JohnsonXarelto$263$59,34358 claims
AstraZenecaFarxiga$114$14,78312 claims
Novo NordiskOzempic$144$13,44014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →